OVAS vs. TSVT, IFRX, LPTX, NVCT, TELO, MNPR, ATOS, PEPG, ANRO, and ENTA
Should you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include 2seventy bio (TSVT), InflaRx (IFRX), Leap Therapeutics (LPTX), Nuvectis Pharma (NVCT), Telomir Pharmaceuticals (TELO), Monopar Therapeutics (MNPR), Atossa Therapeutics (ATOS), PepGen (PEPG), Alto Neuroscience (ANRO), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "medical" sector.
OvaScience vs.
2seventy bio (NASDAQ:TSVT) and OvaScience (NASDAQ:OVAS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.
OvaScience has lower revenue, but higher earnings than 2seventy bio.
2seventy bio presently has a consensus target price of $9.00, suggesting a potential upside of 276.57%. Given 2seventy bio's stronger consensus rating and higher probable upside, equities analysts clearly believe 2seventy bio is more favorable than OvaScience.
2seventy bio has a net margin of -207.25% compared to OvaScience's net margin of -10,128.37%. OvaScience's return on equity of -47.06% beat 2seventy bio's return on equity.
OvaScience received 249 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 63.87% of users gave OvaScience an outperform vote while only 56.82% of users gave 2seventy bio an outperform vote.
2seventy bio has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500.
93.9% of 2seventy bio shares are owned by institutional investors. Comparatively, 22.5% of OvaScience shares are owned by institutional investors. 7.2% of 2seventy bio shares are owned by insiders. Comparatively, 7.4% of OvaScience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, 2seventy bio had 1 more articles in the media than OvaScience. MarketBeat recorded 1 mentions for 2seventy bio and 0 mentions for OvaScience. 2seventy bio's average media sentiment score of 1.88 beat OvaScience's score of 0.00 indicating that 2seventy bio is being referred to more favorably in the media.
Summary
2seventy bio beats OvaScience on 10 of the 17 factors compared between the two stocks.
Get OvaScience News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OvaScience Competitors List
Related Companies and Tools
This page (NASDAQ:OVAS) was last updated on 1/15/2025 by MarketBeat.com Staff
Free OVAS Stock Alerts